Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Emma Platt"'
Autor:
Ayal A. Aizer, Terri L. Warholak, Joni L. Dean, Lea Mollon, Derek H. Tang, Elizabeth Anderson, Lisa E. Davis, Emma Platt
Publikováno v:
Clinical Breast Cancer. 20:e232-e243
PIK3CA mutations may have prognostic value for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, representing an important potential target for systemic therapy. Prognostic and predict
Autor:
Rajeev Ayyagari, David Chandiwana, Emma Platt, Anand A. Dalal, Olivia Liu, Eni Dervishi, Joyce O'Shaughnessy, Oscar Patterson-Lomba
Publikováno v:
The Breast Journal. 25:880-888
Several endocrine-based therapies have recently been evaluated as treatments for premenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC). We conducted a systemati
Autor:
Lea Mollon, Joni L. Dean, Ayal A. Aizer, Lisa E. Davis, Emma Platt, Elizabeth Anderson, Terri L. Warholak, Derek H. Tang
Publikováno v:
International Journal of Breast Cancer
International Journal of Breast Cancer, Vol 2020 (2020)
International Journal of Breast Cancer, Vol 2020 (2020)
PIK3CA mutation frequency varies among breast cancer (BC) subtypes. Recent evidence suggests combination therapy with the PI3K inhibitor (PI3Ki) alpelisib and endocrine therapy (ET) improves response rates and progression-free survival (PFS) in PIK3C
Autor:
Aditya Bardiya, Joni L. Dean, Derek H. Tang, Emma Platt, Lea Mollon, Ayal A. Aizer, Alejandra Aguilar, Terri L. Warholak, Elizabeth Anderson, Lisa E. Davis
Publikováno v:
Cancer Research. 78:2217-2217
Introduction: This systematic literature review sought to determine the concordance of PIK3CA mutations in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) patients. Methods: A
Autor:
Alejandra Aguilar, Elizabeth Anderson, Joni L. Dean, Aditya Bardiya, Derek H. Tang, Emma Platt, Ayal A. Aizer, Lea Mollon, Lisa E. Davis, Terri L. Warholak
Publikováno v:
Cancer Research. 78:1207-1207
Introduction: Clinical research on the predictive value of PIK3CA mutations in hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2–) metastatic breast cancer (mBC) has advanced in recent years. However, knowledge of epid
Autor:
Terri L. Warholak, Alejandra Aguilar, Derek H. Tang, Ayal A. Aizer, Joni L. Dean, Lea Mollon, Emma Platt, Aditya Bardiya, Lisa E. Davis, Elizabeth Anderson
Publikováno v:
Cancer Research. 78:2193-2193
Introduction: This study aimed to identify biopsy and analytical testing methods for PIK3CA mutation in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) via a systematic literat
Autor:
Aditya Bardia, Alejandra Aguilar, Joni L. Dean, Derek H. Tang, Terri L. Warholak, Ayal A. Aizer, Lea Mollon, Emma Platt, Lisa E. Davis, Elizabeth Anderson
Publikováno v:
Journal of Clinical Oncology. 36:e13037-e13037
e13037Background: The predictive and prognostic value of PIK3CA mutation in HR+/HER2–metastatic breast cancer (mBC) is not known. This study aimed to assess clinical prognosis for patients with HR+...